Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $7
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.